Eli Lilly and Company (LLY)

Receivables turnover

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	US$ in thousands	45,042,700	34,124,100	28,541,400	28,318,400	24,539,800
Receivables	US$ in thousands	13,275,400	11,336,200	6,896,000	6,672,800	5,875,300
Receivables turnover		3.39	3.01	4.14	4.24	4.18

December 31, 2024 calculation

Receivables turnover = Revenue ÷ Receivables
= $45,042,700K ÷ $13,275,400K
= 3.39

Eli Lilly and Company's receivables turnover ratio has shown fluctuations over the past five years. In December 2020, the ratio stood at 4.18, slightly increasing to 4.24 by December 2021. However, there was a decrease in the ratio to 4.14 by December 2022. This trend took a sharp turn in December 2023, plunging to 3.01, indicating a potential decline in the efficiency of collecting receivables. By December 2024, the ratio improved to 3.39, but it still remained lower than the levels seen in the earlier years. Overall, the varying receivables turnover ratios suggest changes in the company's ability to collect outstanding receivables efficiently, which may impact its liquidity and working capital management.